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Background: A previous study reported a method for measuring the spectral transmittance of individual human
eyelids. A prototype light mask using narrow-band “green” light (λmax = 527 nm) was used to deliver light through
closed eyelids in two within-subjects studies. The first study investigated whether an individual-specific light dose
could suppress melatonin by 40% through the closed eyelid without disrupting sleep. The light doses were
delivered at three times during the night: 1) beginning (while subjects were awake), 2) middle (during rapid eye
movement (REM) sleep), and 3) end (during non-REM sleep). The second study investigated whether two individual-
specific light doses expected to suppress melatonin by 30% and 60% and delivered through subjects’ closed eyelids
before the time of their predicted minimum core body temperature would phase delay the timing of their dim
light melatonin onset (DLMO).
Findings: Compared to a dark control night, light delivered through eyelids suppressed melatonin by 36% (p= 0.01)
after 60-minute light exposure at the beginning, 45% (p= 0.01) at the middle, and 56% (p< 0.0001) at the end of
the night. In the second study, compared to a dark control night, melatonin was suppressed by 25% (p= 0.03) and
by 45% (p= 0.009) and circadian phase, as measured by DLMO, was delayed by 17 minutes (p= 0.03) and 71
minutes (ns) after 60-minute exposures to light levels 1 and 2, respectively.
Conclusions: These studies demonstrate that individual-specific doses of light delivered through closed eyelids can
suppress melatonin and phase shift DLMO and may be used to treat circadian sleep disorders.
Keywords: Dim light melatonin onset (DLMO), Light, Eyelid transmission, Circadian, MelatoninFindings
Introduction
Retinal light exposures at night can suppress melatonin
and change circadian phase. Many studies have shown
that identical light exposures delivered at different times
of night will have differential impact on the circadian
phase. The valence (positive or negative) of the circadian
phase response curve (PRC) changes from a delaying to
an advancing response to light about 1.5 hours before
normal wakening, near the time of minimum core body
temperature (CBTmin). Moreover, the PRC exhibits
maximal responses to light just before and just after this
phase transition. Therefore, the same exact light dose
can either advance or delay the circadian clock and can* Correspondence: figuem@rpi.edu
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distribution, and reproduction in any mediumhave a large or a small effect on circadian phase,
depending upon the time of night when it is applied
[1,2]. Many studies have shown these effects during the
night while people are awake, but few attempts have
been made to stimulate the retina with light through the
closed eyelid and, in particular, while individuals are
asleep.
Recently, Bierman et al. [3] measured and modeled
eyelid spectral transmittance, showing high attenuation to
short-wavelength light where the human circadian system
is most sensitive. On average, the closed eyelid attenuates
circadian-effective light by approximately two orders of
magnitude, but individual spectral transmittances can vary
by one order of magnitude. Thus, to precisely dose light
for circadian stimulation through a person’s eyelids, it is
necessary to prescribe the spectral irradiance on the eyelid
as it will be attenuated by the spectral transmittance oftral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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developed for the present two studies to provide individua-
lized doses of light for the stimulation of the circadian
system through closed eyelids. The goal of the first study
was to determine if the light delivered through a person’s
eyelids could predictably suppress nocturnal melatonin
while the person slept. The goal of the second study was
to reinforce the nocturnal melatonin suppression results
of the first study and to extend those findings to determine
if an individualized light dose could change circadian
phase. By combining the phototransduction model by Rea
et al. [4] with individually-measured spectral transmittance
functions, it was possible to develop an individually-pre-
scribed dose of light for stimulating the retina through the
closed eyelids. The spectral power distribution of the light
exposure was optimized for circadian system stimulation
[4], transmission through the eyelid [3], and minimization
of blue-light hazard [5], taking into consideration the prac-
tical performance characteristics of commercially available
light-emitting diodes (LEDs). Polysomnography (PSG) was
used to time the delivery of the light dose and to measure
its effect on sleep efficiency.
Methods
Experiment 1: Acute melatonin suppression during sleep
Subjects Six subjects (three females) from 40–65 years
of age (mean ± standard deviation = 48.6 ± 9.33 years)
agreed to participate in the study and were free from any
major health problems, such as cardiovascular disease,
diabetes, or high blood pressure. Subjects were excluded
from the experiment if they were taking over-the-counter
melatonin, antidepressants, sleep medicine, beta block-
ers, or hormone replacement therapy drugs. Each subject
participated in a two-night protocol separated by one
week. Subjects were asked to keep a regular schedule
(bed times before 23:00 h and wake-up times no laterFigure 1 Light mask. Light mask used in the two studies to deliver
individualized dose of 527 nm, “green” light.than 08:00 h) during the weeks prior to the night of data
collection. The night prior to the study, subjects were
asked to go to bed by 22:00 h. To verify compliance,
each subject wore a wrist actigraph (Actiwatch Spectrum
IPX7, Philips Respironics, Pittsburgh, PA, USA) and kept
a sleep log starting one week prior to the experiment.
Subjects were asked to avoid naps and to refrain from
consuming caffeine on the day of the experiment. All
subjects completed a consent form approved by the
Rensselaer Polytechnic Institute Institutional Review
Board [6] and were paid for their participation. The
research was conducted according to the principles
expressed in the Declaration of Helsinki [7].
Light mask Figure 1 shows the light mask used in the
present studies. Green LEDs (λmax = 527 nm, full-width-
half-maximum=36 nm) were selected as the light source
because this wavelength optimizes eyelid spectral
transmission [3] with the spectral sensitivity of the human
circadian system [4]. Also as an important consideration
in light source selection, exposure to high radiances of this
wavelength limits blue light hazard risk relative to shorter
wavelengths [5]. Machined aluminum heat-sinks were
used with the prototype mask to dissipate the heat
generated by the light sources. The light generated by the
prototype mask was controlled by a program that
increased light levels gradually over two minutes from zero
to the prescribed light level, with the assumption that this
temporal ramp would avoid “startling” the subjects with
the light dose while they were asleep.
Lighting conditions Individualized light doses were
determined from the measured spectral transmittance of
one eyelid of each subject and the calculated amount of the
green light irradiating closed eyelids needed to suppress
melatonin by 40% according to the model by Rea et al. [4].
For the calculations of circadian stimulus needed for 40%
suppression, a standard observer was assumed with the fol-
lowing characteristics: pupil diameter= 2.3 mm, circadian
time=2 hours before predicted CBTmin (approximately
03:00 h), exposure duration=60 minutes. Effective light
doses (irradiance x time) on the closed eyelids of each sub-
ject were calculated using the individual-specific eyelid
spectral transmittance data obtained on night 1 utilizing
the methods described by Bierman et al. [3]. Briefly, a nurse
gently lifted each subject’s eyelid from the cornea and then
placed it between the light source and light sensor of a
special “wand” that quickly measures the eyelid spectral
transmittance. As described by Bierman et al., a measure-
ment takes less than 5 s, with no discomfort whatsoever to
the subject. The light mask was then calibrated and its
output adjusted for each subject. The nurse had some diffi-
culty collecting eyelid measurements from one subject due
to excessive squinting and wrinkling of the eyelid during
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the apparatus was going to hurt him. For this subject, the
individually-prescribed dose of light was based upon the
median eyelid transmission of eighteen subjects previously
measured by Bierman and colleagues [3]. The irradiances
predicted to be required by each subject to obtain 40%
melatonin suppression varied from 33 to 85 W/m2 (17,000
to 50,000 lux) at the closed eyelid.
Procedure Each subject participated in a two-night
protocol during the months of October to December
2009. On the days of the experiment, subjects were
asked to arrive at the laboratory at 22:00 h. Upon arrival
to the laboratory, illuminated by conventional ceiling-
mounted fluorescent light sources (OCTRON XP,
3500 K lamp, Sylvania, Danvers, MA, USA) delivering
approximately 100 lux at the cornea, subjects were asked
to wear dark glasses (transmission< 10%) while being
prepared for the experiment. Subjects were fitted with
electrodes for the recording of electroencephalography,
electrooculography, and electromyography used in PSG
(Alice System, Philips Respironics, Pittsburgh, PA, USA).
Using the International 10/20 system, scalp electrodes
were placed at C3, C4, O1, O2, A1, and A2, with a
ground electrode in the middle of the forehead. For elec-
tromyography, one electrode was placed centrally on the
chin and the other on the submentalis muscle. Standard
placement was used for right and left electrooculog-
raphy. A registered nurse inserted an indwelling catheter
into one of the subjects’ veins. The room lights were
turned off at 23:00 h and dim red light (λmax = 640 nm),
< 1 lux at the cornea, was provided to the room by
LEDs for the remainder of the night. Subjects were then
asked to sit in a recliner chair and were outfitted with
the light mask.
On both nights, blood samples for melatonin assays
were collected during three sessions: 1) the initial part of
the night while subjects were awake, 2) the middle of the
night while subjects were asleep in non-rapid eye move-
ment (non-REM), and 3) the latter part of the night while
subjects were asleep during REM. The exact collection
times while subjects were asleep were dependent upon
their sleep stages, which were continuously monitored
throughout the entire experiment by the experimenters
using PSG.
During the first session, subjects were awake, wearing
the light mask. On the first night, the light mask was not
energized, and data from this night served as a baseline.
On the second night, subjects were again awake and
wore the light mask during the first session, but this time
light was delivered through the closed eyelids from
23:30 h until 00:30 h. Blood samples were drawn from
an indwelling catheter every 20 minutes starting 20 min-
utes prior to putting on the light mask. Two sampleswere taken before the light mask was energized and four
samples were taken during the light exposure.
At 01:15 h, subjects began the second and third sessions,
involving data collection while they were asleep in a
reclining chair, wearing the light mask. During the second
session, once a subject entered stage 2 sleep, blood
samples were taken every 30 minutes for a total of three
samples. On night 1, the three samples were all taken
while wearing the un-energized light mask, whereas on
night 2, one blood sample was obtained before energizing
the light mask and two samples were obtained 30 minutes
and 60 minutes after light onset. Session three on both
nights began at the onset of REM sleep. On night 1, three
blood samples were drawn when the light mask was not
energized, whereas on night 2, one sample was obtained
before the light mask was to be energized for 60 minutes.
Subsequent samples were obtained 30 minutes and 60
minutes later; on night 2, the samples were taken during
light exposure. The applications of the light stimuli during
the second and third sessions of both nights were
separated by at least 45 minutes to ensure that melatonin
concentrations would rise after the first light exposure.Data analyses Blood samples were spun for 15 minutes
at 1000x g for plasma extraction on the night of sample
collection. Plasma samples were then frozen (−20°C) and
later sent to a laboratory (Pharmasan, Osceola, WI,
USA) for melatonin radioimmunoassay. The sensitivity
of the plasma assay was 3.5 pg/ml and the intra- and
inter-assay coefficients of variability were 8.1% and
14.8%, respectively.
A 3 (sleep condition: awake, non-REM, and REM) x 2
(light mask dark/control and light exposure) analysis of
variance (ANOVA) was used to compare melatonin concen-
trations after 60 minutes of light exposure or of darkness.
Two-tailed, paired Student’s t tests were used to further
compare the significant main effects and interactions.
Melatonin suppression was calculated using the ratio
of the melatonin concentrations obtained on night 1
(dark) and those obtained near the same clock time on
night 2 (light on). Melatonin concentrations were
normalized to minimize unwanted differences among
individuals. The normalization factors for every subject
were determined by dividing the mean of melatonin
concentration for all subjects and all experimental
conditions by the mean of each subject’s melatonin
concentrations for all experimental conditions. All the data
from a subject were then multiplied by their own
normalization factor. Two-tailed, One-Sample T tests were
used to determine whether melatonin suppressions after
light exposures were significantly different than zero. A
criterion level for Type I errors at a probability of 0.05 was
used for all of the statistical tests.
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phase shifts
Subjects Seven subjects (two females) with mean ±
standard deviation age 23 ± 7 years agreed to participate
in the study, were screened for major health problems,
and reported abstention from pharmaceuticals or medi-
cations. All subjects provided written informed consent
approved by Rensselaer’s Institutional Review Board [6]
and were paid for their participation. The research was
conducted according to the principles expressed in the
Declaration of Helsinki [7]. Subjects were asked to
refrain from alcohol and caffeine on the days of the
experiment.
Every potential subject completed a Munich Chron-
otype Questionnaire prior to the study, and those who
were late or extremely late chronotypes were excluded
from the experiment [8]. All of the selected subjects
were asked to maintain a regular sleep/wake schedule
starting one week prior to the study and continuing
during the three weeks of the experiment to minimize
differences in circadian phase among subjects. To help
ensure compliance, participants completed a sleep/
wake diary during all weeks of the experiment, and
wore wrist actigraphs (Actiwatch Spectrum IPX7, Phi-
lips Respironics, Pittsburgh, PA, USA) on the non-
dominant wrist starting one week prior to the first
night in the laboratory. These data were examined be-
fore subjects were approved for participation in data
collection.
Procedures Experiment 2 was conducted from June to
August 2010. All subjects arrived at the laboratory
between 18:30 h and 20:30 h on a Thursday, and each
session concluded approximately 30 hours later, between
00:00 h and 02:00 h on a Saturday. Subjects’ arrival times
were based on their estimated dim light melatonin onset
(DLMO), which was calculated using their self-reported
sleep times [9]. The protocol consisted of three
experimental conditions, each presented during a separate
session, at least one week apart from each other. The light
masks used were identical to those in Experiment 1. The
first night was a control (dark) night when eyelid spectral
transmittances were measured for each subject. Subjects
wore the un-energized light mask while they slept. The
subjects were presented the two other experimental
conditions over the course of two weeks, in a counterba-
lanced order. Light level 1 (LL1) was a lower light level
and light level 2 (LL2) was a higher light level. Based on
calculations performed using the model of human
circadian phototransduction by Rea and colleagues [4] and
the individually-measured eyelid spectral transmittances,
LL2 delivered from the light mask was set for every subject
to suppress nocturnal melatonin by 60% and LL1 was set
to suppress nocturnal melatonin by 30%.The room lights were turned off at 18:30 h and dim
red (λmax = 640 nm) light, <1 lux at the cornea, was
provided to the room by LEDs for the remainder of the
night. Starting from 18:50 h to 20:50 h depending on the
individual estimated DLMO, saliva samples were
collected every 20 minutes for 5 hours, to assess DLMO
phase. Saliva collection was done using the Salivette
system (Sarstedt, Newton, NC, USA). To prevent
contamination of the saliva samples, the subjects were
only allowed to sip water right after each saliva collection
time. No drinking was allowed 15 minutes prior to each
saliva sample collection. No eating was allowed during
DLMO data collection period.
Before being allowed to sleep, a registered nurse inserted
an indwelling catheter into one of the subjects’ veins. After
DLMO collection ended, the subjects were given the
opportunity to sleep and were awakened the following
morning at 09:00 h. While the subjects were sleeping, the
light mask was activated two hours prior to their estimated
CBTmin, which was defined for this experiment as equiva-
lent to seven hours after predicted DLMO. This should
have placed the light exposure in the delay portion of the
PRC. Therefore, DLMO was expected to be delayed on
the second night of the protocol with respect to that
measured on the first (dark, control) night. The light
always remained on for 60 minutes. Two blood samples
were drawn from the indwelling catheter 40 minutes and
20 minutes prior to light exposure and 30 minutes and
60 minutes after light onset. Thus, a total of four blood
samples were collected while subjects slept. After the
fourth blood sample was collected, the indwelling catheter
and light mask were removed. If subjects were awake, they
were allowed to return to sleep.
From 09:00 h until 18:30 h, subjects remained in dim
red light and were allowed to perform normal computer
work, read, and play games. Electronic devices (i.e.,
computers, phones, portable media players) were dimmed
to the lowest possible brightness and were covered with an
orange filter (Roscolux #21 Golden Amber, Rosco,
Stamford, CT, USA) that removed short wavelengths.
Transmittance through the filters from 380 to 550 nm was
2.1%. Napping was not allowed during the experiment.
Breakfast, lunch, and dinner were offered at specific times.
Subjects were asked to brush their teeth after dinner,
which was offered 60 minutes prior to data collection.
Saliva samples were collected every 20 minutes for 6
hours, starting at 19:00 h or at 20:50 h to assess DLMO
phase. After the last saliva sample was collected, subjects
were allowed to go home.
Data analyses and phase shift calculations Saliva
samples were frozen (−20°C) after collection and later
sent to a laboratory (Pharmasan, Osceola, WI, USA) for
melatonin radioimmunoassay. The sensitivity of the
Figure 2 Normalized melatonin concentrations for Experiment
1. Mean ± SEM melatonin concentrations for all subjects in the first
study. As shown on the far left, the mean melatonin concentrations
on night 2 (after light exposure) were significantly lower than on
night 1 (dark night); mean suppression after 60-minute light
exposure was 46%. The melatonin concentrations on night 2 were
significantly lower than the comparable concentrations on night 1
while subjects were awake (mean suppression after 60-minute light
exposure was 36%), during non-REM sleep (mean suppression 45%),
and REM sleep (mean suppression after 60-minute light exposure
was 56%).
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coefficients of variability were 12.1% and 13.2%,
respectively.
Melatonin concentrations and acute melatonin
suppression A 3 (dark, LL1, and LL2) x 4 (sample col-
lection times) ANOVA was performed on the normalized
melatonin concentrations. Two-tailed, paired Student’s t
tests were used to further compare the significant main
effects and interactions.
Melatonin suppression was calculated using the ratio
of the melatonin concentrations obtained on night 1
(dark) and those obtained near the same clock time on
night 2 (energized light mask). Two-tailed, One-Sample
T tests were used to determine whether melatonin
suppressions after light exposures were significantly dif-
ferent than zero. For all of the statistical tests, a criterion
probability level of 0.05 for a Type I error was used.
Phase shifting Melatonin profiles for each subject on
each night (dark, LL1, and LL2) were fitted with a locally
weighted least-squares curve [10,11]. DLMO threshold
was calculated by taking the mean of the five lowest
continuous melatonin concentrations plus 15% of the
five highest continuous values. DLMO for each mela-
tonin profile was the time (as determined by linear
interpolation) that the fitted curve reached and remained
above the calculated DLMO threshold [12]. If the fitted
curve had not reached and remained above the calcu-
lated DLMO threshold by the end of the data collection
period, DLMO time was taken be at the last data collec-
tion time. Phase shifting was determined by subtracting
the time of DLMO determined for the control night
(Saturday night that subjects remained in the dark) from
the time of DLMO determined for the light exposure
night (Saturday night following nocturnal light expos-
ure). As an arbitrary convention, a negative remainder
indicates that the nocturnal light exposure was asso-
ciated with a delay in circadian phase.
Two-tailed, One-Sample T tests were used to deter-
mine whether the phase shifts obtained after exposure to
LL1 and LL2 were significantly different than zero (i.e.,
no different than a natural phase shift in the dark).
Results
Experiment 1: Acute melatonin suppression during sleep
Figure 2 shows the overall mean ± standard error of the
mean (SEM) normalized melatonin concentrations (pg/ml)
for nights 1 (un-energized light mask) and 2 (energized
light mask) as well as the melatonin concentrations at the
three different times of the night and sleep stages (start/
awake, middle/non-REM, and end/REM). A 3 (time of
night/sleep stage) x 2 (light mask energization) ANOVA
revealed a significant main effect of light mask energization(F1,5 = 21.2; p=0.006). The mean ± SEM normalized mela-
tonin concentration on night 1 was 71 ± 16 pg/ml, while
on night 2 it was 36 ± 16 pg/ml. The main effect of time of
night/sleep stage was not statistically significant (F2,10 = 3.6;
p=0.07), nor was the interaction between the two variables
(F2,10 = 0.3; p=0.8). Simple two-tailed, paired Student’s
t tests were performed comparing melatonin concentra-
tions at each of the three times of the night/sleep stages
(start/awake, middle/non-REM, and end/REM), with and
without light mask energization. There was a significant
difference in melatonin concentrations between nights 1
and 2 when subjects were awake (p=0.007), during non-
REM (p=0.02), and during REM (p=0.0002) sleep.
The mean ± SEM suppression after 60-minute light
exposure was 36 ± 9% in the first part of the night
(awake), 45 ± 12% in the middle part of the night (non-
REM), 56 ± 7% in the latter part of the night (REM).
Melatonin suppression by the light through the eyelids
was very close to predicted values (40%) during the mid-
dle of the night. Two-tailed, One-Sample T tests revealed
that melatonin suppression was significantly greater than
zero after light exposure at the start (p= 0.01), middle
(p= 0.01), and end of the night (p< 0.0001).PSG Results Based upon the PSG reports, the mean
sleep efficiency on night 1 was 76 ± 5%, while on night 2
(energized light mask) was 78 ± 5%. The mean total sleep
time was 200 ± 15 min on night 1 and 222± 15 min on
night 2, and the mean wakefulness after sleep onset was
83 ± 22 min on night 1 and 74 ± 21 min on night 2.
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2 (REM sleep), subjects were awake for only 6 ± 3 min.Experiment 2: Acute melatonin suppression and circadian
phase shifts
Melatonin concentrations Figure 3 shows the mean
normalized melatonin concentrations. The ANOVA
revealed the main effect of light was not statistically
significant (F2,10 = 3.5; p= 0.07), but there was a signifi-
cant main effect of sample time (F3,15 = 20.1, p <0.0001)
and there was a significant interaction between the two
variables (F6,30 = 4.8; p= 0.002).
As shown in Figure 3, LL2 was a stronger stimulus for
suppressing melatonin than LL1. To further analyze the
significant light x sample collection time interaction, two-
tailed, paired Student’s t tests revealed that melatonin
concentrations after 60 minutes in the dark (control night)
were significantly higher than melatonin concentrations
after 60 minutes of exposure to LL1 (p=0.03) and to LL2
(p=0.01).
Nocturnal melatonin suppression was calculated by
taking the ratio of the melatonin concentrations after
exposure to LL1 or LL2 and melatonin concentrations in
the dark/control night after 60-minute exposures. As
expected, suppression was greater after exposure to LL2
than after exposure to LL1; the mean suppression levels
were 25 ± 9% for LL1 and 45 ± 12% for LL2. Two-tailed,
One-Sample T tests revealed that melatonin suppressionsFigure 3 Normalized melatonin concentrations for Experiment
2. Mean ± SEM melatonin concentrations for the seven subjects
who completed the second, three-night, within-subjects study. The
first two measurements were collected prior to turning on the mask.
The last two measurements were collected 30 and 60 minutes after
the light mask was energized (except for the dark, control night
when the mask remained off for the duration of the experiment).
Nocturnal melatonin suppression levels were 25% and 45% after 60-
minute light exposures to the LL1 and LL2, respectively.after exposure to LL1 and LL2 were significantly differ-
ent than zero (p= 0.03 for LL1 and p= 0.009 for LL2).Phase shifting Figure 4 shows the estimated change in
DLMO, in minutes, induced by the light exposures rela-
tive to the dark control night. Subjects 23 and 25 did not
have melatonin concentrations above the DLMO thresh-
old by 02:10 h, so, as noted above, the time of the last
saliva sample collection was used as a conservative esti-
mate of their DLMO times. The mean ± SEM relative
phase shift was −17 ± 6 minutes after exposure to LL1
and −70 ± 41 minutes after exposure to LL2. Two-tailed,
One-Sample T tests revealed that LL1 was significantly
different than zero (p = 0.032) but LL2 was not (p= 0.14),
despite having a greater mean phase shift. The median
phase shift was −24 minutes after exposure to LL1 and
−13 minutes after exposure to LL2.Discussion
The results of both studies showed that individually-
prescribed light stimuli delivered through closed eyelids
were sufficient to suppress melatonin while subjects were
awake and while they were asleep. Importantly, the
prescribed light levels, estimated using the eyelid spectral
transmission values at 527 nm for each subject and theFigure 4 Change in circadian phase. Change in circadian phase,
as measured by DLMO, for seven subjects who completed the
second, three-night study. A negative value indicates that DLMO was
delayed relative to the dark, control night as a result of the light
exposure. Mean± SEM for the low and high light levels are also
shown. Note that some subjects had similar phase shifts and their
data are overlapping in the graph.
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colleagues [4], resulted in average melatonin suppression
levels close to the predicted values. It should be noted,
however, that the prescribed light delivered by the light
mask did not suppress melatonin for one of the subjects in
the first study. According to her eyelid measurements, she
had high eyelid transmittance, so she had the lowest
prescribed light dose in either study. She also had
unusually low melatonin concentrations in the dark. It
may be that the low prescribed light level and/or her low
melatonin concentrations contributed to her negative
findings. She also described herself as a “light sleeper”
which may have also affected her results. Her PSG report
showed numerous awakening episodes throughout the
course of the night, with a total of 100 micro arousals
compared to a mean of 42 micro arousals per night experi-
enced by the other subjects. Notwithstanding the data for
this one subject, the eyelid spectral transmission measure-
ment procedure together with the model of nocturnal
melatonin suppression can be used with some confidence
to prescribe an individual light dose through a person’s
closed eyelid.
The present melatonin suppression findings are not
necessarily inconsistent with others in the literature
where light was delivered to the retina through closed
eyelids. Hatonen et al. [13] exposed subjects to 2,000 lux
of white light (True-Lite fluorescent lamps, 5500 K) at
the eyelid, with eyes opened and closed, and were able to
demonstrate significant melatonin suppression only in
the setting of opened eyes. Two out of eight subjects
decreased their melatonin concentrations by the light
exposure through the closed eyelids, but on average,
melatonin concentrations were not significantly different
from the control night (dim light). These results are
consistent with our predictions based upon the average
eyelid transmission estimates from Bierman et al. [3].
Using these average eyelid transmission values, subjects
should have received approximately 40 lux at the cornea
from the 5500 K light source, mostly from long
wavelengths, so the eyelid-filtered “white” light would be
largely ineffective for suppressing melatonin and
activating the circadian system. Based upon the high
variability found in eyelid transmission among indivi-
duals [3], it is not unexpected that two of the eight sub-
jects in the Hatonen et al. study [13] could have
suppressed melatonin. If these two subjects indeed had
high eyelid transmittances, the white light might have
provided a sufficient light stimulus to suppress some
melatonin through their closed eyelids.
Phase shifting responses to the light delivered by the
light mask were shown in the second study. Unlike the
close correspondence between the predicted and the
observed melatonin suppression, the observed magnitudes
and directions of the phase shifts in DLMO were morelikely to differ from the predicted magnitudes and direc-
tions. As is commonly accepted [9,14], personal sleep log
data were used to prescribe the individualized times of
light dose delivery to achieve the desired changes in circa-
dian phases. As shown by Crowley et al. [14] and Burgess
and Eastman [9], however, actual DLMO cannot be
precisely predicted from sleep logs, particularly for sub-
jects on a strict schedule, as in this study. If, for example,
actual DLMO is advanced a couple hours with respect to
predicted DLMO, a light dose prescribed for a modest
phase delay would be applied closer to the cross-point in
the PRC, resulting in a much larger phase delay than
expected, or even a phase advance. Thus, the observed
magnitudes and directions of phase shift will be increas-
ingly more variable the closer the light is applied near the
cross-point in the PRC.
As pointed out in the results section, two subjects in
this experiment had much stronger phase delay
responses to LL2 than the other subjects. The only night
we were not able to determine DLMO for these two sub-
jects was on night 2 after exposure to LL2 (post treat-
ment night). DLMO was determined for these two
subjects in all other nights, including the dark, control
night. Consistent with the above rationale, the observed
DLMO for both of these subjects on the dark, control
night was much earlier than the DLMO predicted from
the sleep logs. One of these subjects who showed a very
large phase delay to LL2 showed a phase advance to LL1.
Thus, light stimuli were likely delivered to these two
subjects at times closer to the respective cross-points of
their PRC. A strong circadian stimulus, such as the one
delivered by LL2, if given on the phase delay side, but
close to the cross-point, may lead to a very large phase
delay, similar to the ones observed after exposure to LL2
in these two subjects. If the same stimulus is, however,
split between the two sides of the cross-point (i.e., ad-
vance and delay portions of the PRC), it can result in a
smaller net phase shifting because it may have induced
some phase delay and some phase advance, reducing the
overall effect of the light exposure. Yet, a third subject
who had a much earlier observed DLMO than was pre-
dicted from the sleep logs exhibited phase advances fol-
lowing exposures to both LL1 and LL2, as would be
expected if the majority of the light exposure was deliv-
ered after the cross-point of the PRC. This subject exhib-
ited a small phase delay following the control (dark)
night, which would be consistent with a free running
period slightly greater than 24 hours. His light exposure
ended close to 05:15 h, so it is quite possible that at least
some of the light exposure was in the phase advance por-
tion of his PRC, which would explain his net phase ad-
vance in DLMO.
Although it is very appealing to consider using light
delivery through the eyelid while people sleep to
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better able to predict the timing of the cross-point of the
PRC, light delivery with the mask should be early in the
night for a phase delay response or about an hour before
wake-up times for phase advance to assure that light is
delivered in the correct side of the PRC. Again, these
results clearly show the ability of light delivered through
the eyelid to suppress melatonin and phase shift DLMO;
however, the ability to precisely control magnitude and
direction is compromised when using sleep log data.
One previous study also looked at circadian phase
shifting by light through closed eyelids. Cole and collea-
gues [15] used a light mask that exposed subjects to
2,700 lux of white light on closed eyelids. In comparison
to a placebo light (0.1 lux of red light), they demon-
strated significant melatonin phase shifts only among
select patients with delayed sleep phase disorder, but not
among subjects who are normally entrained to the 24-hr
light/dark cycle. The authors suggest that the light mask
in that study was energized 4 hours prior to the
scheduled time of rising, so the long duration may have
illuminated a less responsive portion of the PRC or it
may have induced some phase delay prior to inducing
phase advances, reducing the overall effect of the light
treatment. Based upon the average eyelid transmission
values from Bierman and colleagues [3], however, the
white light would have delivered approximately 57 lux at
the cornea. Similar to the post hoc inferences drawn
from Hatonen et al. [13] study of melatonin suppression,
the marginal phase-shifting effects found by Cole and
colleagues may be have been due, at least in part, to the
low, eyelid-filtered light levels on the cornea and the
high individual differences in eyelid transmittances.
Finally, it is important to emphasize that most subjects
were able to sleep while light was being applied through
their eyelids. Observations by the experimenters were
consistent with participants’ subjective impressions, as
well as with the PSG scores in the first study. Although
some subjects briefly woke up when the mask reached
full light output the first time at night, they went back to
sleep shortly thereafter. The light did not awaken most
of the subjects during REM sleep. In fact, at the conclu-
sion of the experiment, when asked how many times the
light mask was turned on at night, all subjects said they
only noticed it once. In some instances subjects were
awakened when the nurse was drawing the blood, but
again, they reported going back to sleep right away. In
both studies, none of the subjects reported opening their
eyes during the light exposure, especially because they
were instructed to avoid doing so because the light
would be uncomfortably bright. Furthermore, based on
observations by the experimenters from both studies, all
subjects were asleep (i.e., snoring or not exhibiting
activity) a few minutes after the blood samples werecollected and when masks were energized. Even if they
had seen the light flash directly, the radiance would be
uncomfortably bright and natural photophobic response
would cause them to close their eyes immediately. The
fact that we used a 527-nm light minimized the risk for
blue light hazard if subjects briefly opened their eyes.
Therefore, even if subjects had briefly opened their eyes
during the light exposure period, this brief light exposure
was determined to be below the threshold for blue light
hazard. In fact, the Institutional Review Board reviewed
and approved our calculations performed for eyes open
and eyes closed. If subjects opened their eyes during the
light exposure, the brief, but very bright flash of light
may have, however, resulted in some phase shifting or
acute melatonin suppression. We do not believe this was
the case given that, as mentioned before, none of the
subjects reported opening their eyes and, if awakened, all
subjects were instructed to keep their eyes closed at all
times. Moreover, it should be noted that a single, very
brief light exposure would not be expected to have much
effect on phase shifting. Zeitzer et al. [16] showed phase
shifting after 60 exposures to brief, very bright light
pulses, but not after a single exposure. Thus, it is
unlikely that the results observed here are artifacts of
brief eye openings during the study.
In summary, although the results are very clear with
respect to suppressing melatonin through closed eyelids,
our ability to predict the magnitude and direction of
phase shifting was much more variable, probably because
circadian phase cannot be precisely predicted from sleep
log data. The closer light is delivered to the time when
the PRC changes from phase delay to phase advance, the
more variable the magnitude and the direction of the
phase shift will be. Nevertheless, a more in-depth set of
studies needs to be conducted examining potential
artifacts of light exposure through closed eyelids and
examining other populations, such as patients with
actual circadian sleep disorders. A light mask similar to
the one tested here can possibly be used to effectively
treat circadian sleep disorders, such as delayed sleep
phase disorder experienced by young adults or early
morning chronic insomnia experienced by older adults.
Moreover, user acceptance of a light treatment device for
field use also has to be conducted. Based on our observa-
tions in the laboratory and on informal interviews the
following day, subjects seemed to be able to sleep
through the light exposure period without waking or
experiencing discomfort. Considering that the light mask
employed in the present study was not particularly
comfortable, these results are quite encouraging for
further experimentation and product development. A
light mask that delivers stimuli through closed eyelids
(during sleep) may offer a practical means of circumvent-
ing barriers to phototherapy compliance and can lead to
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pharmacological treatment modality for circadian sleep
disorders. Future research should further test the light
mask in clinical applications.
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